AX-2025-019812 · Semaglutide · Homopeptide lot HOMO-2501-A5192

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.90	% area	≥ 97.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.10	% area	≤ 3.0	PASS
Largest single impurity	RP-HPLC — C18 diacid mono-ester	0.07	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4111.0524	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4111.0224	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-7.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	85.99	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.90	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.21	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	4.475	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	89.5	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	6.45	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.37	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.19	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.12	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	15.56	min	15.60 ± 0.45 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.30	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,452	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib8]-diastereomer	0.78	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,452, and skew follows the reported asymmetry factor of 1.30. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.07 % impurity against a 99.90 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Semaglutide — main peak	15.56	4,855,450	99.90	—
2	C18 diacid mono-ester	16.69	3,402	0.07	+14.016
3	[D-Aib8]-diastereomer	15.36	972	0.02	0.000
4	Met(O) sulfoxide (+16 Da)	14.99	486	0.01	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4111.0524 Da, computed from C187H291N45O59. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4111.0224 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	686.1827	686.1777	-0.0050	8.6
5+	823.2178	823.2118	-0.0060	52.1
4+	1028.7704	1028.7629	-0.0075	100.0
3+	1371.3581	1371.3481	-0.0100	53.4
2+	2056.5335	2056.5185	-0.0150	7.9

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	6.45
Counter-ion (TFA)	ion chromatography	7.37
Residual solvent + inorganic residue	estimated	0.19
Total peptide content	by difference	85.99
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.90	divergence +0.14 pp vs batch median
Total impurities (% area)	0.10	0.10
Largest single impurity (% area)	0.06	0.07
Water (%)	5.8	6.45
Counter-ion (%)	3.7	7.37
Peptide content (%w/w)	89.9	85.99
Endotoxin (EU/mg)	0.58	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 29 d since original receipt) → re-assay.
Assay date: 05 Apr 2025
Submitted to the index: 23 Apr 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

c18_2p623 Apr 2025

Column chemistry flatters or punishes a figure like this. A core-shell column at this gradient resolves the close-eluting family that a fully porous 5 µm bed merges, so 99.90 % here is a harder number than the same figure from a coarser column.

ms_confirm23 Apr 2025

Purity at 99.90 % with identity confirmed on the same submission is the combination worth having. Either alone leaves a question the other answers.

racemisation_ala23 Apr 2025

Epimerisation during activation produces a diastereomer that is mass-identical and only chromatographically separable. At this gradient length the separation exists, and 99.90 % is net of it.

hplc_ola23 Apr 2025

Column temperature shifts selectivity by a few percent per ten degrees on peptides. Where two peaks are this close that is enough to matter and it is rarely on the report.

Section 7

Related records

Same batch — lot HOMO-2501-A5192 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-019813	HOMO-2501-A5192	Janoshik	2025-Q2	99.52	6.29	—	Buyer-sourced	PASS
AX-2025-019814	HOMO-2501-A5192	Janoshik	2025-Q2	99.75	5.38	107.3	Buyer-sourced	PASS
AX-2025-019815	HOMO-2501-A5192	Janoshik	2025-Q2	99.60	5.85	—	Buyer-sourced	PASS
AX-2025-019816	HOMO-2501-A5192	Kestrel	2025-Q2	99.93	6.25	102.4	Buyer-sourced	PASS
AX-2025-019817	HOMO-2501-A5192	Janoshik	2025-Q2	99.76	5.25	107.0	Buyer-sourced	PASS
AX-2025-019818	HOMO-2501-A5192	Medutest	2025-Q2	99.93	5.59	92.8	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Semaglutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043376	WXT	WXT-2604-C3248	Janoshik	2026-Q3	97.08	4.22	—	Buyer-sourced	1	MARGINAL
AX-2026-042424	Homopeptide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	0	PASS
AX-2026-041643	FGP	FGP-2602-M8547	Janoshik	2026-Q3	99.31	2.79	100.7	Buyer-sourced	0	PASS
AX-2026-041334	WWB	WWB-2606-N3192	Janoshik	2026-Q3	98.93	4.62	99.9	Buyer-sourced	0	PASS
AX-2026-042002	AMB	AMB-2607-N6274	VendorInvestigate	2026-Q3	98.23	6.37	97.1	Buyer-sourced	1	MARGINAL
AX-2026-041337	WWB	WWB-2606-N3192	Nordanalyt	2026-Q3	99.52	3.92	—	Buyer-sourced	0	PASS
AX-2026-042595	HJ	HJ-2608-C7002	Janoshik	2026-Q3	99.50	3.55	—	Buyer-sourced	1	MARGINAL
AX-2026-042217	TFC	TFC-2604-X9037	PeptideMeter	2026-Q3	98.95	4.61	96.9	Buyer-sourced	0	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS